// App-Quantinova.ai

9030 : 4-year overall survival for patients with advanced NSCLC treated with pembrolizumab: Results from KEYNOTE-001.

Researchers

Presenter

  • Enriqueta Felip

Principal Investigators

  • Matthew David Hellmann

  • Rina Hui

  • Enric Carcereny

  • Natasha B. Leighl

  • Myung-Ju Ahn

  • Joseph Paul Eder

  • Ani Sarkis Balmanoukian

  • Charu Aggarwal

  • Leora Horn

  • Amita Patnaik

  • Matthew A. Gubens

  • Suresh S. Ramalingam

  • Erin Jensen

  • Debra A. Kush

  • Edward B. Garon

Medical Centers

  • Vall d Hebron University Hospital (HUVH) and Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain

  • Memorial Sloan Kettering Cancer Center, Port Washington, NY

  • Westmead Hospital and University of Sydney, Sydney, Australia

  • Medical Oncology Department. Catalan Institute of Oncology, Hospital Germans Trias i Pujol, Badalona, Spain

  • Princess Margaret Cancer Center, Toronto, ON, Canada

  • Yale University, New Haven, CT

  • The Angeles Clinic and Research Institute, Los Angeles, CA

  • Abramson Cancer Center, Philadelphia, PA

  • Vanderbilt University Medical Center, Nashville, TN

  • START-South Texas Accelerated Research Therapeutics, LLC, San Antonio, TX

  • University of California, San Francisco, San Francisco, CA

  • Winship Cancer Institute of Emory University, Atlanta, GA

  • Merck & Co., Inc., Kenilworth, NJ

  • David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA

Locations

  • United States

  • Spain

  • Canada

  • Australia

Companies

  • Merck & Co., Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • N/A

Biomarkers

  • Programmed death-ligand 1

Drug/Treatment

  • Pembrolizumab

Outcome

  • N/A

Study Design

  • N/A

Phase

  • I

Study Id's

  • NCT01295827

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved